Item 7.01 Regulation FD Disclosure.

Included as Exhibit 99.1 to this Form 8-K is a corporate presentation dated January 2022 that is incorporated herein by reference. We intend to utilize this presentation and its contents in various meetings with securities analysts, investors and others, including in connection with the H.C. Wainwright BioConnect Virtual Conference, commencing on January 10, 2022.

The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits. (d) Exhibits.

Exhibit No. Description


   99.1       Longboard Pharmaceuticals Corporate Presentation dated January 2022
    104     Cover Page Interactive Data File (embedded within the Inline XBRL document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses